Tiragolumab联合阿替利珠单抗及化疗治疗晚期非鳞非小细胞肺癌:3期SKYSCRAPER-06随机临床试验
SKYSCRAPER-06是一项3期随机临床试验,评估Tiragolumab联合阿替利珠单抗及化疗对比安慰剂联合帕博利珠单抗及化疗一线治疗晚期非鳞非小细胞肺癌的疗效与安全性。主要终点无进展生存期和总生存期均未达到,研究已终止。
要点
- Tiragolumab联合阿替利珠单抗及化疗未改善无进展生存期和总生存期。
- 试验组中位无进展生存期8.3个月,对照组9.9个月,风险比1.27。
- 试验组3-4级不良事件发生率61.4%,与对照组60.7%相近。
核心结论
- 3期SKYSCRAPER-06研究主要终点未达到,研究已终止。
研究设计与样本
- 3期随机临床试验,纳入542例既往未治疗的局部晚期不可切除或转移性非鳞非小细胞肺癌患者。
- 患者1:1随机接受Tiragolumab 600 mg联合阿替利珠单抗1200 mg及化疗,或安慰剂联合帕博利珠单抗200 mg及化疗。
- 主要终点为研究者评估的无进展生存期和总生存期。
主要发现
- 3-4级不良事件发生率试验组61.4%(164/267),对照组60.7%(165/272);5级不良事件分别为10.1%(27/267)和5.9%(16/272)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Programmed cell death 1 ligand 1/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, survival benefit is limited, and many patients experience disease progression. OBJECTIVE: To evaluate the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC. DESIGN, SETTING, AND PARTICIPANTS: SKYSCRAPER-06 was a phase 3 randomized clinical trial that recruited patients with previously untreated, locally advanced unresectable or metastatic NSCLC at 129 sites in 21 countries between December 15, 2020, and September 14, 2023 (data cutoff, April 19, 2024). INTERVENTION: Patients were randomized 1:1 to receive either tiragolumab, 600 mg, plus atezolizumab, 1200 mg, plus chemotherapy (pemetrexed, 500 mg/m2, and carboplatin [area under the curve 5], or cisplatin, 75 mg/m2) or placebo plus pembrolizumab, 200 mg, plus chemotherapy via intravenous infusion on day 1 of each 21-day cycle until disease progression, loss of clinical benefit, unacceptable toxic effect, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: Primary end points were investigator-assessed progression-free survival and overall survival. The safety and tolerability of the study drugs were also evaluated. RESULTS: Of 542 patients in the full analysis set (mean [SD] age, 63.6 [9.3] years; 353 [65.1%] male), 269 were randomized to tiragolumab plus atezolizumab plus chemotherapy and 273 to placebo plus pembrolizumab plus chemotherapy. Overall, baseline demographics were similar between treatment groups. At data cutoff (median follow-up, 11.8 months), median investigator-assessed progression-free survival was 8.3 months (95% CI, 7.1-9.6 months) with tiragolumab plus atezolizumab plus chemotherapy vs 9.9 months (95% CI, 8.7-11.9 months) with placebo plus pembrolizumab plus chemotherapy (hazard ratio, 1.27; 95% CI, 1.02-1.57; P = .99); median overall survival was 18.9 months (95% CI, 15.2-23.8 months) vs 23.1 months (95% CI, 20.7-33.0 months) in each treatment group, respectively (hazard ratio, 1.33; 95% CI, 1.02-1.73; P = .98). Grade 3 to 4 adverse events occurred in 164 of 267 patients (61.4%) in the tiragolumab plus atezolizumab plus chemotherapy group and 165 of 272 patients (60.7%) in the placebo plus pembrolizumab plus chemotherapy group, with grade 5 AEs occurring in 27 of 267 patients (10.1%) and 16 of 272 patients (5.9%) in each group, respectively. CONCLUSIONS AND RELEVANCE: In the phase 3 SKYSCRAPER-06 randomized clinical trial, the primary end points were not met and the study has been terminated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04619797.
引用
- Socinski MA, Stahel R, Lee DH, et al. Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42060297. doi:10.1001/jamaoncol.2026.0818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。